Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29653552 | 0.85 | EPHX2 (0.44) | ENPP2CA1CA2EPHX2CYP11B1 | |
| SCHEMBL41862 | 0.85 | EPHX2 (0.44) | ENPP2CA1CA2EPHX2CYP11B1 | |
| SCHEMBL3316135 | 0.83 | CA1 (0.47) | ENPP2CA1CA2LMNAGAA | |
| SCHEMBL4628852 | 0.78 | EPHX2 (0.46) | CA1CA2EPHX2CYP11B1CYP11B2 | |
| SCHEMBL10656799 | 0.77 | ALDH1A1 (0.49) | CA1CA2EPHX2CYP11B1CYP11B2 | |
| SCHEMBL29427761 | 0.77 | ALDH1A1 (0.49) | CA1CA2EPHX2CYP11B1CYP11B2 | |
| SCHEMBL12261025 | 0.76 | L3MBTL1 (0.48) | ENPP2PGRARMAPTSMN1; SMN2 | |
| SCHEMBL263475 | 0.75 | TUBB4A (0.43) | ENPP2CA1CA2MAPTNPSR1 | |
| SCHEMBL16384318 | 0.75 | SMN1; SMN2 (0.39) | CA2CYP11B1CYP11B2ARLIPE | |
| SCHEMBL21446957 | 0.75 | CYP11B1 (0.44) | CA1CA2EPHX2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2784065-B1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-9242938-B2 | Glycine reuptake inhibitor and use thereof | BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) | 2015-05-14 | — | — | US | disclosed |
| EP-2784065-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | Beijing Medisan Technology Co. Ltd. (CN) | 2014-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133497-A1 | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | SLC6A2, SLC6A5, SLC6A4 | ENPP2 2907/4885CA1 1688/4885CA2 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.